Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per share of -51 cents missing Wall Street’s estimate of -43 cents. That’s despite the company’s losses improving from the -$1.44 reported in Q4 2023.
Novavax also reported revenue of $88.31 million in its most recent earnings report, beating analysts’ estimate of $83.47 million. However, it represents a 69.68% drop year-over-year from revenue of $291.34 million. This comes as the company shifts focus away from its COVID-19 vaccine to maximizing the value of its technology platform through pipeline expansion and partnerships.
Novavax investors are pleased with the company’s most recent earnings report, sending shares 1.37% higher in pre-market trading. That follows a 2.09% increase yesterday ahead of its earnings report. The stock has also dropped 8.96% year-to-date but remains up 65.99% over the past 52 weeks.
Novavax 2025 Guidance
Novavax doesn’t provide overly detailed guidance for investors. The company simply notes it expects Combined R&D and SG&A Expenses to range from $475 million to $525 million.
One thing that is worth noting is Novavax selling its Nuvaxovid COVID-19 vaccine to Sanofi (SNY). for the 2025 to 2026 flu season. It doesn’t have an outlook for royalties and product sales from this change. The only guidance it provides for this is Adjusted Licensing, Royalties and Other Revenue of $300 million to $350 million.
Novavax President and CEO John Jacobs said, “As we look to 2025 and beyond, we believe we are well positioned to potentially create significant value for all stakeholders.”
Is NVAX Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Novavax is Moderate Buy based on two Buy and two Hold ratings over the last three months. With that comes an average price target of $15.50, a high of $22, and a low of $9. This represents a potential 111.75% upside for NVAX stock. These ratings and price targets will likely change as analyst update their coverage after today’s earnings report.
